A comparison of the pharmacokinetics of antithrombin derived from human plasma and from transgenic goats and the prevention of sepsis in an animal model

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 6, 2008, Pages 356-365

  Dickneite, Gerhard ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

Antithrombin; Drug evaluation,preclinical; Kybernin; Pharmacokinetics; Sepsis

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III CONCENTRATE; BACTERIUM LIPOPOLYSACCHARIDE; PLACEBO; TRANSGENIC ANTITHROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; ESCHERICHIA COLI; FEMALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MORTALITY; NONHUMAN; OPEN STUDY; PARALLEL DESIGN; PLASMA CONCENTRATION-TIME CURVE; RABBIT; RAT; SEPSIS; SURVIVAL TIME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTITHROMBINS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GOATS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; RABBITS; RANDOM ALLOCATION; RATS; SEPSIS; SURVIVAL RATE;

EID: 53349097915     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.623     Document Type: Article

References (36)

1. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. Antithrombin: the principal inhibitor of thrombin. Semin Thromb Hemost 1994; 20: 353-372.
2. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-670.
3. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 415-4020.
4. Hoffmann JN, Vollmar B, Romisch J, Inthorn D, Schildberg FW, Menger MD. Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002; 30: 218-225.
5. Hoffmann JN, Vollmar B, Laschke MW, et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 242-252.
6. Dickneite G, Kroez M. Treatment of porcine sepsis with high-dose antithrombin III reduces tissue edema and effusion but does not increase risk for bleeding. Blood Coagul Fibrinolysis 2001; 12: 459-467.
7. Carlstrom AS, Lieden K, Bjork I. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. Thromb Res 1977; 11: 785-797.
8. Fourrier F. Therapeutic applications of antithrombin concentrates in systemic inflammatory disorders. Blood Coagul Fibrinolysis 1998; 9 (Suppl 2): S39-S45.
9. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a metaanalysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24: 663-672.
10. Schuster HP. AT III in septicemia with DIC. Intensive Care Med 1993; 19 (Suppl 1): S16-S18.
11. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998; 24: 61-69.
12. Yeung PK. Transgenic antithrombin III (Genzyme). Drugs 2000; 3: 669-673.
13. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-1123.
14. Murakami K, McGuire R, Cox RA, et al. Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep. Crit Care Med 2003; 31: 577-583.
15. Konkle BA, Bauer KA, Weinstein R, Greist A, Holmes HE, Bonfiglio J. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43: 390-394.
16. Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130: 107-113.
17. Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 4561-4571.
18. Hesselvik JF, Blomback M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17: 724-733.
19. Hack CE. Inhibitor substitution in sepsis. Intensive Care Med 1993; 19 (Suppl 1): S1-S2.
20. Massignon D, Lepape A, Bienvenu J, Barbier Y, Boileau C, Coeur P. Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis 1994; 24: 36-48.
21. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823.
22. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 1993; 69: 98-102.
23. Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 1999; 19: 1566-1572.
24. Frantzen Handeland G, Abildgaard U, Aasen AO. Simplified assay for antithrombin III activity using chromogenic peptide substrate. Manual and automated method. Scand J Haematol 1983; 31: 427-436.
25. Dickneite G. Pharmacology of the physiological and peptidomimetic inhibitors of thrombin. Nova Acta Leopoldina 1999; 311: 25-36.
26. Van Cott KE, Velander WH. Transgenic animals as drug factories: a new source of recombinant protein therapeutics. Expert Opin Investig Drugs 1998; 7: 1683-1690.
27. World Health Organization: WHO International Biological Reference Preparations (Blood Products and Related Substances). Geneva, WHO, 2006. Available at http://www.who.int/bloodproducts/catalogue/ bpromay06.pdf (accessed 7 May 2007).
28. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998; 38: 540-549.
29. van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116: 876-883.
30. Liu D, Cramer CC, Scafidi J, Davis AE, 3rd. N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the C1 inhibitor are required for interaction of the C1 inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A. Infect Immun 2005; 73: 4478-4487.
31. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878.
32. Kienast J, Juers M, Wiedermann CJ, et al. KyberSept Investigators. Treatment effects of high-dose antithrombin III without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4: 90-97.
33. Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-292.
34. Weimer T, Streichert S, Watson C, Grösner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma tools for fractionation. Transfusion 2001; 41: 1500-1504.
35. Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res 2002; 105: 391-400.
36. Gröner A, Nowak T, Römisch J. Purity, activity, and virus safety of a pasteurized antithrombin concentrate. Semin Thromb Hemost 2002; 28 (Suppl 1): 79-85.